Core Viewpoint - Honeywell has amended its agreement to acquire Johnson Matthey's Catalyst Technologies business, reducing the total consideration from £1.8 billion to £1.325 billion and extending the long stop date to July 21, 2026 [1]. Group 1 - The total consideration for the acquisition has been adjusted to £1.325 billion [1]. - The long stop date for the transaction has been extended to accommodate outstanding requirements [1].

Core Insights - AIxCrypto Inc. has launched Season 2 of its AIxC Hub, introducing updated engagement mechanics and new features aimed at enhancing AI agent-driven experiences within the ecosystem [1] - The company has seen significant growth in its social media presence, with its official X account reaching 53,417 followers and a 94% increase in engagement rates, alongside total impressions nearing 600,000 [1] - AIxCrypto is refocusing its strategy on Real-World Assets (RWA) and Embodied AI (EAI), transitioning away from certain initiatives to enhance operational focus and capital discipline [1] Company Developments - The launch of Season 2 of AIxC Hub marks a new phase in the company's ecosystem evolution, with additional details on engagement and rewards to be released soon [1] - The strategic refinement includes a concentration of resources on FFAI EAI initiatives, such as intelligent electric vehicles and AI robotics, while discontinuing the BesTrade AI Agent and Digital Asset AI Management modules [1] - AIxCrypto aims to leverage high-quality, multimodal real-world behavioral data to develop AI-integrated blockchain applications, connecting on-chain systems with real-world signals [1] Strategic Outlook - The company is positioned at the intersection of AI, RWA, and crypto infrastructure, focusing on building compliant asset rails to facilitate the integration of real-world assets into blockchain systems [1] - AIxCrypto's goal is to enable smarter AI-native financial and consumer applications, creating practical utility for users, partners, and shareholders [1] - The company emphasizes its commitment to enhancing its core infrastructure objectives while aligning execution efforts with areas of long-term relevance [1]

TAIPEI, Feb. 22, 2026 /PRNewswire/ -- CTCI Group announced that two Group companies, CTCI Corporation and ECOVE Environment Corporation, have been included as members of the Sustainability Yearbook 2026, published by S&P Global. CTCI Corp. received a score of 89 and continues to rank in the top 1% of the yearbook, leading the global construction and engineering category for the fourth consecutive year. Resource cycling service provider ECOVE Environment Corp., meanwhile, became a yearbook member for the sec ...

Core Viewpoint - CStone Pharmaceuticals has received a new indication approval from the UK MHRA for sugemalimab as a monotherapy for adult patients with unresectable stage III NSCLC, expanding its therapeutic applications and commercial potential globally [1][4]. Group 1: Product Approval and Indications - Sugemalimab is now approved as a monotherapy for adult patients with unresectable stage III NSCLC with PD-L1 expression on 1% of tumor cells and no sensitizing EGFR mutations or ALK, ROS1 genomic aberrations [1][5]. - The approval is based on the GEMSTONE-301 study, which showed statistically significant improvement in progression-free survival (PFS) and clinically meaningful prolongation of overall survival (OS) for patients with stage III NSCLC [4]. Group 2: Market Expansion and Commercialization - Sugemalimab has become one of only two PD-(L)1 antibodies approved for stage III NSCLC in Europe since its initial EU approval in July 2024, with a commercial footprint now extending to over 60 countries and regions [2][4]. - The product has been included in multiple national reimbursement systems, indicating its recognized clinical value and pharmacoeconomic benefit [2]. Group 3: Future Development and Regulatory Strategy - CStone plans to advance regulatory filings for sugemalimab in additional indications, including gastric cancer and esophageal squamous cell carcinoma [2]. - The company has established four commercialization partnerships for sugemalimab across Europe, the Middle East, Africa, and Latin America, actively rolling out its global commercial strategy [4]. Group 4: Company Overview - CStone Pharmaceuticals, established in late 2015, focuses on the research and development of therapies for oncology and other key disease areas, having launched 4 innovative drugs and secured approvals for 20 new drug applications covering 9 indications [6]. - The company's pipeline includes 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines [6].

BOCA RATON, Fla., Feb. 22, 2026 /PRNewswire/ -- Do Boca Raton condo owners need their own insurance even if their HOA has a policy? AHelloNation article answers this question by breaking down how HOA insurance works and where individual condo owners are still financially responsible. The article provides clear guidance on what is—and isn't—covered under master policies and why personal condo insurance remains essential. Continue Reading Speed Speed Ellie Mills, President of Mills Insurance Agency Inc The ar ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against PayPal Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and revenue outlook during the specified class period [2][4]. Group 1: Lawsuit Details - The lawsuit is titled Goodman v. PayPal Holdings, Inc., et al, and was filed in the United States District Court for the Northern District of California [2]. - The class period for the lawsuit is from February 25, 2025, to February 2, 2026, and investors have until April 20, 2026, to file for lead plaintiff status [6]. - Allegations include that PayPal's management misrepresented the company's projected revenue and growth, downplaying risks associated with seasonality and macroeconomic factors [4]. Group 2: Stock Performance - On February 3, 2026, PayPal announced a leadership change, replacing its CEO, which coincided with the release of its fourth quarter and full year 2025 earnings report [5]. - The earnings report revealed that PayPal missed consensus estimates for both revenue and profit, leading to a significant stock price drop of $10.63, or 20.3%, closing at $41.70 per share [5]. Group 3: Investor Actions - Investors who purchased PayPal common stock and experienced losses are encouraged to contact Kessler Topaz Meltzer & Check, LLP for potential recovery options [3][6]. - The firm offers a free case evaluation and operates on a contingency fee basis, meaning there is no upfront cost to the investors [7].

Core Viewpoint - Franco-Nevada Corporation has announced a significant financing package of A$220 million (approximately $155 million) with Minerals 260 to support the development of the Bullabulling Gold Project in Western Australia, marking Franco-Nevada's largest royalty acquisition in Australia [1] Group 1: Transaction Details - Franco-Nevada will acquire a gross royalty of A$170 million (approximately $120 million) from Minerals 260, increasing its total gross royalty on the Bullabulling land package to 2.45% [1] - The financing package includes a subscription for A$50 million (approximately $35 million) of Minerals 260's ordinary shares, resulting in Franco-Nevada owning approximately 4.9% of Minerals 260's issued shares [1][2] - The initial A$75 million royalty funding is expected to occur around February 26, 2026, with a second A$95 million funding contingent on obtaining FIRB approval [2] Group 2: Project Overview - The Bullabulling Gold Project is located approximately 65 km from Kalgoorlie, Western Australia, with existing resources of 3.0 million ounces (Moz) of Indicated Resources and 1.5 Moz of Inferred Resources [1] - The project has significant exploration potential, with a large resource base covering multiple deposits and a recent drilling campaign that nearly doubled the mineral resources since 2011 [1] - A pre-feasibility study is targeted for completion by mid-2026, with a final investment decision expected in early 2027, and first gold production potentially as soon as the second half of 2028 [1] Group 3: Management and Expertise - Minerals 260 is led by experienced management, including Chairman Tim Goyder, who has over 40 years in the resource industry, and CEO Luke McFadyen, who has over 15 years of mining experience [1] - The management team's expertise is expected to facilitate the rapid advancement of the Bullabulling project and unlock value for shareholders [1]

The platform integrates Wonder Cognitiveâ"¢- proprietary Cognitive Twin technology with real-time clinical escalation pathways designed to address the growing safety crisis in AI mental health LOS ANGELES, Feb. 22, 2026 /PRNewswire/ -- VIVE Conference — Wonder Sciences today announced the pilot launch of WonderMate, an AI digital therapist and clinical co-pilot built from inception around established therapeutic frameworks, longitudinal cognitive modeling, and human-led safety escalation. Pilot sign-ups are ...

Decker to Make Official Debut with Team Venturi at Atlanta Motor Speedway on July 11 ATLANTA, Feb. 22, 2026 /PRNewswire/ -- Venturi Bold Brew, the performance-driven coffee brand redefining premium energy, proudly announces a new partnership with NASCAR driver Natalie Decker. Decker will make her first official appearance as a driver for Team Venturi at the highly anticipated July 11th race in Atlanta, Georgia. This partnership signals a bold new chapter for both Venturi Bold Brew and Natalie Decker uniting ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against Oracle Corporation, alleging material misstatements regarding its data center capabilities for AI infrastructure and capital expenditures during the class period from June 12, 2025, to December 16, 2025 [1] Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Barrows v. Oracle Corporation, was filed on February 3, 2026, in the United States District Court for the District of Delaware [1] - Investors who purchased Oracle common stock during the class period may seek to serve as lead plaintiff by April 6, 2026 [1] Allegations - The complaint alleges that Oracle misled investors by overstating its contracts for AI infrastructure development and falsely assuring that significant capital expenditures would lead to rapid revenue growth [1] - Specific allegations include: 1. Oracle's AI infrastructure strategy would lead to substantial increases in capital expenditures without corresponding near-term revenue growth [1] 2. Increased spending posed risks to Oracle's debt, credit rating, free cash flow, and project funding [1] 3. Defendants' statements regarding Oracle's business and prospects were materially false and misleading [1] Investor Actions - Investors are encouraged to retain legal counsel or contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation [1] - The lead plaintiff process allows investors to represent the class and direct the litigation, with the deadline for filing set for April 6, 2026 [1]